SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Targacept (TRGT)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: keokalani'nui who wrote (18)1/26/2007 3:39:51 PM
From: tuckRead Replies (1) of 40
 
Starting to look at TRGT. From the 3rd Q PR posted by George:

>>Completed the dosing phase of Targacept's ongoing Phase II trial of
mecamylamine hydrochloride as an add-on therapy for depression in
August. Targacept believes that the results of the trial, which are
expected to be available in the fourth quarter of 2006, may provide
valuable insights that can be applied to the development of TC-2216.<<

Well, we haven't seen those results yet. They are presumably right around the corner. I don't know how much market cap is at risk with the trial, and I haven't looked at the design or biological rationale . . . in other words, I am currently clueless. Maybe I can look this weekend, ut I was wondering of you had a view regarding outcome of this event.

TIA & Cheers, Tuck
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News